Browse KIR2DS2

Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein.
Domain PF00047 Immunoglobulin domain
Function

Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells.

> Gene Ontology
 
Biological Process -
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04612 Antigen processing and presentation
hsa04650 Natural killer cell mediated cytotoxicity
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-2172127: DAP12 interactions
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KIR2DS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between KIR2DS2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25381437GlioblastomaPromote immunity (NK cell function)NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KIR2DS2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KIR2DS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0450.961
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592.070.323
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-2.7230.323
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1110.247
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIR2DS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIR2DS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIR2DS2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIR2DS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KIR2DS2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KIR2DS2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKIR2DS2
Namekiller cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2
Aliases cl-49; nkat5; 183ActI; CD158J; NKAT-5; CD158 antigen-like family member J; NK receptor 183 ActI; killer-cell ......
Chromosomal Location19q13.4 alternate reference locus
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KIR2DS2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.